Compare FSUN & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSUN | GLPG |
|---|---|---|
| Founded | 1892 | 1999 |
| Country | United States | Belgium |
| Employees | 1186 | 704 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | N/A | N/A |
| Metric | FSUN | GLPG |
|---|---|---|
| Price | $39.40 | $29.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $45.33 | $36.50 |
| AVG Volume (30 Days) | ★ 253.8K | 191.0K |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $79.34 | N/A |
| Revenue Next Year | $14.67 | N/A |
| P/E Ratio | $11.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.95 | $24.74 |
| 52 Week High | $42.34 | $37.78 |
| Indicator | FSUN | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 64.87 | 42.14 |
| Support Level | $37.45 | $28.78 |
| Resistance Level | $40.24 | $34.04 |
| Average True Range (ATR) | 1.40 | 0.64 |
| MACD | 0.35 | 0.15 |
| Stochastic Oscillator | 85.08 | 52.52 |
Firstsun Capital Bancorp is the financial holding company. It provides a full range of deposit, lending, treasury management, wealth management, and online banking products and services. The company operates in two segments; Banking operations and mortgage operations, the majority of which are generated by the banking operations segment. The Banking segment originates loans and provides deposits and fee based services to consumer, business, and mortgage lending customers. Products offered include a full range of commercial and consumer banking and financial services. The Mortgage Operations segment originates, sells, services, and manages market risk from changes in interest rates on one-to-four family residential mortgage loans.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.